

Supplemental Information


Heterogeneity of phase II enzyme ligands on controlling the progression of human gastric cancer organoids as stem cell therapy model

Deng-Chyang Wu¹⁻⁴, Chia-Chen Ku¹⁻³, Jia-Bin Pan¹⁻³, Kenly Wuputra¹⁻³, Ya-Han Yang^{2,4}, Chung-Jung Liu²⁻⁵, Yi-Chang Liu³, Kohsuke Kato⁶, Shigeo Saito⁷, Ying-Chu Lin⁸, Inn-Wen Chong^{1,9,10}, Michael Hsiao¹¹, Huang-Ming Hu^{4,12}, Chao-Hung Kuo^{4,13}, Kung-Kai Kuo^{2,4}, Chang-Shen Lin¹, and Kazunari K. Yokoyama^{1-3*}

¹Graduate Institute of Medicine, ²Regenerative Medicine and Cell Therapy Research Center, Kaohsiung Medical University, Kaohsiung 807, Taiwan, ³Cell Therapy and Research Center, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan, ⁴Division of General and Digestive Surgery, department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan, ⁵Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan. ⁶Department of Infection Biology, Graduate School of Comprehensive Human Sciences, the University of Tsukuba, Tsukuba 305-8577, Japan. ⁷Saito laboratory of Cell Technology, Yaita 239-1571, Tochigi, Japan, ⁸School of Dentistry, Kaohsiung Medical University, Kaohsiung 807, Taiwan, ⁹Division of Pulmonary and Critical Care Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan, ¹⁰Department of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsinchu 300193, Taiwan. ¹¹Genome Research Center, Academia Sinica, Nangan, Taipei 115, Taiwan, ¹²Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung 80145, Taiwan, ¹³Department of Internal Medicine, Kaohsiung Municipal Siaogang Hospital 812, Taiwan.

*Authors to whom correspondence should be addressed; Kazunari K. Yokoyama (kazu@kmu.edu.tw); Cell Therapy and Research Center, Kaohsiung Medical University Hospital; Department of Medicine, Graduate Institute of Medicine, Kaohsiung Medical University, Taiwan, Tel; +886-7312. 1001, ext 2729; FAX; +886-7313-3849). ORCID of C-C Ku; 0000-0002-1496-3081; C-S Lin; 0000-0001-7415-2187; K.K. Yokoyama; 0000-0001-8508-7587.


*Authors to whom correspondence should be addressed; Kazunari K. Yokoyama (kazu@kmu.edu.tw); Cell Therapy and Research Center, Kaohsiung Medical University Hospital; Graduate Institute of Medicine, Kaohsiung Medical University, Taiwan, Tel; +886-7312. 1001, ext 2729; FAX; +886-7313-3849). ORCID of C-C Ku; 0000-0002-1496-3081; C-S Lin; 0000-0001-7415-2187; K.K. Yokoyama; 0000-0001-8508-7587.



Supplemental Figure S1.


Imaging of drug screening of 3-D organoids cultivation. The ~500 μm of organoids which were generated by digestion with TrypLE reagents and seeded organoids sparsely in Transwells as monolayers (~30 organoid fragments per dome of ~20 μL , about 50,000 cells) with one dome per well of a 24-well plate. For the xenotransplantation assay, we injected organoids in scid mice (~100 organoid fragments per dome of ~200 μL , about 150,000 cells) [56].

Fig 4C



A

Fig 6a



B

Supplemental Figure S2.

Uncropped raw data of western blots that were used in this article. Results are provided according to the sequence mentioned in the main text (**A**) Figure 4c and (**B**) Figure 6a. The red rectangles represent regions that were cropped to use in the figures of this article.